Travere Therapeutics' Net Cash Flow rose 870.50% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 169.99%. This contributed to the annual value of $1.3 million for FY2024, which is 100.50% up from last year.
Travere Therapeutics' Net Cash Flow amounted to $35.6 million in Q3 2025, which was up 214.55% from $11.3 million recorded in Q2 2025.
Over the past 5 years, Travere Therapeutics' Net Cash Flow peaked at $91.8 million during Q1 2022, and registered a low of -$147.7 million during Q3 2023.
For the 3-year period, Travere Therapeutics' Net Cash Flow averaged around -$18.7 million, with its median value being $2.8 million (2025).
Per our database at Business Quant, Travere Therapeutics' Net Cash Flow surged by 1,275.15% in 2021 and then plummeted by 216.10% in 2022.
Quarterly analysis of 5 years shows Travere Therapeutics' Net Cash Flow stood at -$41.6 million in 2021, then slumped by 169.60% to -$112.2 million in 2022, then grew by 26.80% to -$82.2 million in 2023, then skyrocketed by 128.10% to $23.1 million in 2024, then skyrocketed by 870.50% to $35.6 million in 2025.
Its last three reported values are $35.6 million in Q3 2025, $11.3 million for Q2 2025, and $2.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value